Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$140.24 USD

140.24
1,040,622

-1.97 (-1.39%)

Updated Jun 20, 2024 04:00 PM ET

After-Market: $140.24 0.00 (0.00%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 249)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

DaVita HealthCare (DVA) closed the most recent trading day at $140.24, moving -1.39% from the previous trading session.

Veeva's (VEEV) Vault EDC to Boost Vita Global's Data Management

Veeva's (VEEV) Vault EDC is likely to improve Vita Global's clinical data management processes.

McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.

Patterson Companies (PDCO) Q4 Earnings Miss, Sales Rise Y/Y

Patterson Companies' (PDCO) fourth-quarter fiscal 2024 results reflect a year-over-year improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales improve.

Venus Concept's (VERO) Latest Supply Deal to Aid its Business

Venus Concept (VERO) announces an exclusive strategic supply arrangement with Skin Laundry Holdings, Inc.

BrainsWay (BWAY) Inks Distribution Agreement to Expand Foothold

BrainsWay's (BWAY) latest exclusive multi-year distribution agreement is likely to provide improved patient care in Canada.

Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Philips' (PHG) Diagnosis & Treatment Segment Drives Growth

Philips (PHG) boosts Diagnosis & Treatment on the back of Precision Diagnosis and Image-Guided Therapy businesses and an expanding partner base.

Merit Medical (MMSI) Recalls Syringes Made by Jiangsu Shenli

Merit Medical (MMSI) recalls certain products containing syringes made by a Chinese manufacturer, Jiangsu Shenli.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

GE HealthCare's (GEHC) New Tie-Up to Boost Patient Care in Mexico

GE HealthCare's (GEHC) latest agreement is likely to standardize care protocols and improve the quality of CT, MR and ultrasound examinations.

Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy

Allurion (ALUR) announces positive weight loss data for its gastric balloon technology.

Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure

Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.

3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

DaVita HealthCare (DVA) Stock Declines While Market Improves: Some Information for Investors

DaVita HealthCare (DVA) reachead $142.16 at the closing of the latest trading day, reflecting a -0.37% change compared to its last close.

Patterson Companies' (PDCO) Launch to Boost Insurance Workflow

Patterson Companies' (PDCO) latest offering is likely to offer customers additional options for their electronic insurance processing and patient billing statement workflow.

HealthEquity (HQY) Gains 25.3% YTD: What's Driving the Rally?

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA

Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.

Philips (PHG) Aids Image-Guided Treatment With New Stent System

Philips (PHG) boosts its Image-Guided Therapy portfolio with the Duo Venous Stent System, strengthening its Diagnosis & Treatment segment.

Urmimala Biswas headshot

3 PEG-Based Value Picks to Boost Your Portfolio Returns

Invest in shares of Eldorado Gold (EGO), Sasol (SSL) and DaVita (DVA) that hold huge upside potential.

DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?

DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.

Here's Why You Should Retain Integer Holdings (ITGR) Stock

Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.